In part 1 we discussed the issues with the decades-long practice of healthcare providers prescribing behavior-based weight loss not based on the evidence (which shows that the vast majority of patients will lose weight short-term and then regain it long-term) but on the belief/hope that every one of their patients will experience the very rare “Best Case Scenario” of significant, sustained weight loss. Today we’re going to talk about how the new GLP-1 weight loss drugs are taking this problem to new lows.

Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe